Human Immunodefieciency Virus: Pharmacogenetics of Antiretroviral Treatment

Pesoa, Susana; Bioch, Cristian A Galván

doi:10.4172/2153-0645.s6-002

Cited by 1 publication

(3 citation statements)

References 68 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, TDF is not a substrate for MRP2, but for MRP4 15 . More recently, a naïve association between ABCC4 3463A>G genotype and renal toxicity has been reported showing tenofovir concentrations 35 per cent higher in carriers of the 3463G variant 44 .…”

Section: Pharmacogenomicsmentioning

confidence: 99%

“…P-glycoprotein acts as a NNRTI carrier. The association between variants of MDR1 gene and NNRTI plasma concentrations has been studied comprehensively 44 .…”

Section: Pharmacogenomicsmentioning

confidence: 99%

“…Also, significantly higher NVP plasma levels are reported in black patients heterozygous for T983C SNP 16 17 . Although sex, age, body mass index, habits, habitat and pathological liver condition are major criteria in influencing pharmacokinetics of NVP, but in most of the studies only body weight is included 29 44 57 .…”

Section: Pharmacogenomicsmentioning

confidence: 99%

See 2 more Smart Citations

Individualization of antiretroviral therapy - Pharmacogenomic aspect

Dalal¹,

Shankarkumar²,

Ghosh³

2015

Indian J Med Res

View full text Add to dashboard Cite

Combination therapy with three drug regimens for human immunodeficiency virus (HIV) infection significantly suppresses the viral replication. However, this therapeutic impact is restricted by adverse drug events and response in terms of short and long term efficacy. There are multiple factors involved in different responses to antiretrovirals (ARVs) such as age, body weight, disease status, diet and heredity. Pharmacogenomics deals with individual genetic make-up and its role in drug efficacy and toxicity. In depth genetic research has provided evidence to predict the risk of developing certain toxicities for which personalized screening and surveillance protocols may be developed to prevent side effects. Here we describe the use of pharmacogenomics for optimal use of HAART (highly active antiretroviral therapy).

show abstract

Section: Pharmacogenomicsmentioning

confidence: 99%

“…P-glycoprotein acts as a NNRTI carrier. The association between variants of MDR1 gene and NNRTI plasma concentrations has been studied comprehensively 44 .…”

Section: Pharmacogenomicsmentioning

confidence: 99%